Ipsen logo

Ipsen(OTC) IPSEF

Market Cap$12.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)+177%
5 Year+69%
1 Year+38%
1 Month+38%
$153.99
+0.00%
+0.00Today
Ipsen last closing stock price
MetricPriceDate
Last closeUSD 153.992026-10-09
Ipsen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+38.39%USD 111.272026-07-31
1 month+38.39%USD 111.272026-07-31
3 month+38.39%USD 111.272026-07-06
Year to date+38.39%USD 111.272025-12-26
1 year+38.39%USD 111.272025-09-19
3 year+36.46%USD 112.842023-09-21
5 year+69.3%USD 90.962021-10-01
Since inception+176.55%USD 55.682007-10-18

Ipsen Financials at a Glance

Market Cap

$12.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€8.56B

Net Income (TTM)

€1.08B

EPS (TTM)

$7.21

P/E Ratio

21.30

Dividend

$1.86

Beta (Volatility)

-0.01 (Low)

Price

$153.99

Volume

203

Open

$153.99

Previous Close

$153.99

Daily Range

$153.99 - $153.99

52-Week Range

$113.13 - $153.99

Estimated Earnings Date

Feb 11, 2027

IPSEF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ipsen

Ipsen S.A. is a biopharmaceutical company focused on developing and commercializing innovative medicines in oncology, rare diseases, and neuroscience. With a strong global presence, Ipsen aims to address unmet medical needs through its diverse portfolio of products.

Products and Services
  • Oncology treatments like Somatuline and Cabometyx
  • Rare disease therapies including Bylvay and Iqirvo
  • Neuroscience products such as Dysport for migraine treatment
Growth Outlook
  • Recent quarterly revenue reached €2.19 billion, indicating strong market demand
  • Ongoing clinical trials for innovative therapies may enhance product pipeline
  • Strategic partnerships could expand market reach and accelerate growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of €8.4 billion reflects robust performance
  • Net income for the latest quarter was €402 million, showcasing profitability
  • Dividend yield of 1.12% offers potential income for investors
Ipsen S.A. has established itself as a key player in the biopharmaceutical industry, with a focus on addressing critical health challenges. The company's diverse product offerings in oncology, rare diseases, and neuroscience position it well for future growth. Recent financial performance highlights, including a significant quarterly revenue and net income, underscore the company's operational strength. Additionally, ongoing clinical trials and strategic partnerships may further enhance Ipsen's market position and growth potential. Investors may find Ipsen's commitment to innovation and strong financial metrics appealing as they consider opportunities in the healthcare sector.
AI Generated • Sep 30, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

5,535

CEO

David G. Loew, MBA

Website

www.ipsen.com

Headquarters

Paris, IF 75015, FR

IPSEF Financials

Key Financial Metrics (TTM)

Gross Margin

67.52%

Operating Margin

30.13%

Net Income Margin

12.67%

Return on Equity

11.33%

Return on Capital

14.34%

Return on Assets

6.87%

Earnings Yield

4.69%

Dividend Yield

1.21%

Payout Ratio

25.71%

Stock Overview

Market Cap

$12.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

82.71M

Volume

203

Avg. Volume

104.031

Financials (TTM)

Gross Profit

€6.58B

Operating Income

€2.43B

EBITDA

€2.72B

Operating Cash Flow

€2.36B

Capital Expenditure

-€866.68M

Free Cash Flow

€1.49B

Cash & ST Invst.

€1.97B

Total Debt

€961.76M

Ipsen Performance Analysis

Ipsen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 3,179,197,3081.8%
20232023-12-31EUR 3,381,189,0486.4%
20242024-12-31EUR 3,678,397,5868.8%
20252025-12-31EUR 4,148,539,68912.8%
Ipsen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31208.1%
Q22025-06-30-20.6%
Q42025-12-31-28.6%
Q22026-06-3042.9%
Ipsen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 8.20-10.5%
20232023-12-31EUR 8.361.9%
20242024-12-31EUR 4.49-46.3%
20252025-12-31EUR 6.0033.8%
Ipsen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3185.5%
Q22025-06-3075.1%
Q42025-12-31-87.0%
Q22026-06-30695.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€2.19B

+149.7%

Gross Profit

€1.75B

+144.2%

Gross Margin

80.13%

N/A

Market Cap

$12.74BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.30M

N/A

Employees

5,535

N/A

Net Income

€402.50M

+247.0%

EBITDA

€852.52M

+127.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€1.97B

+305.3%

Total Debt

€961.76M

+96.2%

Accounts Receivable

€998.30M

+38.8%

Inventory

€201.00M

-26.3%

Long Term Debt

€702.45M

+97.8%

Short Term Debt

€259.31M

+91.9%

Return on Assets

6.87%

N/A

Return on Invested Capital

21.29%

N/A

Free Cash Flow

€650.72M

+60.0%

Operating Cash Flow

€679.08M

+45.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$42.52+13.63%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$110.54-13.35%
TQQQProShares Trust - ProShares UltraPro Qqq
$74.12-5.95%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$36.00+5.93%

Questions About IPSEF

What is the current price of Ipsen?

Ipsen is trading at $153.99 per share.

What is the 52-week range for Ipsen?

Over the past 52 weeks, Ipsen has traded between $113.13 and $153.99.

How much debt does Ipsen have?

As of the most recent reporting period, Ipsen reported total debt of €1.14B.

How much cash does Ipsen have on hand?

Ipsen reported €1.79B in cash and cash equivalents in its most recent financial results.

What is Ipsen’s dividend yield?

Ipsen currently has a dividend yield of 1.21%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services